Clinical significance and prognostic value of S100A4 and matrix metalloproteinase-14 in patients with organ-confined bladder cancer

Sagara,Yuji; Miyata,Yasuyoshi; Iwata,Takahisa; Kanda,Shigeru; Hayashi,Tomayoshi; Sakai,Hideki; Kanetake,Hiroshi

doi:10.3892/etm_00000005

Clinical significance and prognostic value of S100A4 and matrix metalloproteinase-14 in patients with organ-confined bladder cancer

Authors:
- Yuji Sagara
- Yasuyoshi Miyata
- Takahisa Iwata
- Shigeru Kanda
- Tomayoshi Hayashi
- Hideki Sakai
- Hiroshi Kanetake
View Affiliations

Affiliations: Department of Urology, Nagasaki University School of Medicine, Nagasaki, Japan
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000005
Pages: 27-31

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Various therapeutic modalities are available for treatment of bladder cancer, and their effectiveness and patient outcome often depend on cancer cell invasiveness. However, the mechanisms underlying the early steps of bladder cancer cell invasion remain unknown. This study aimed to clarify the relationships between S100A4 expression and bladder cancer invasion of surrounding muscles, prognosis and expression of matrix metalloproteinase (MMP)-14 in patients with organ-confined bladder cancer. S100A4 and MMP-14 expression was analyzed in 85 cases of organ-confined (pTa, pT1 and pT2) bladder cancer using immunohistochemical technique. The expression levels were compared among the pTa, pT1 and pT2 tumors. In addition, the predictive values of S100A4 or MMP-14 expression for muscle invasion, metastasis and survival were investigated, as was the possible correlation between the expression of the two proteins. The proportion of S100A4-positive cancer cells in pT2 tumors (53%) was significantly higher (p<0.001) than in pTa (38.7%) or pT1 (40.9%) tumors; there was no difference between pTa and pT1. The results were similar for MMP-14 expression, which was significantly correlated with S100A4 expression (r=0.360, p<0.001). S100A4 expression predicted metastasis-free survival (p=0.009), but not cause-specific survival. The results implicated S100A4 in the early steps of muscle invasion via MMP-14, but not for mucosal invasion. S100A4 is therefore a potential therapeutic target for bladder cancer, and its expression is a risk factor for muscle invasion in patients with superficial tumors. In addition, S100A4 expression may be a useful prognostic factor for metastasis in patients with organ-confined bladder cancer.

View Figures

View References

1.	Heizmann CW, Fritz G and Schafer BW: S100 proteins: structure, functions and pathology. Front Biosci. 7:d1356–d1368. 2002.
2.	Ebralidze A, Tulcinsky E, Grigorian M, Afanasyeva A, Senin V, Revazova E and Lukanidin E: Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca²⁺-binding protein family. Genes Dev. 3:1086–1093. 1989.
3.	Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R and Cheng L: The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol. 22:1025–1032. 2007.
4.	Matsumoto K, Irie A, Satoh T, Ishii J, Iwabuchi K, Iwamura M, Egawa S and Baba S: Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology. 70:602–607. 2007.
5.	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2007.
6.	Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Haffermann MD and Hawkins IR: Superficial bladder cancer: progression and recurrence. J Urol. 130:1083–1086. 1983.
7.	Sternberg S, Donat J, Bellmunt R, Millikan W, Stadler P, De Mulder A, Sherif H, von der Maase T, Tsukamoto M and Soloway M: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy and metastatic cancer. Urology. 69:62–79. 2007.
8.	Bellmunt J, Albiol S and Kataja V; EMSO Guidelines Working Group: Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 19(Suppl 2): 47–48. 2008.
9.	Garrett SC, Varney KM, Weber DJ and Bresnick AR: S100A4, a mediator of metastasis. J Biol Chem. 281:677–680. 2006.
10.	Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25:9–34. 2006.
11.	Bjørnland K, Winberg JO, Odegaard OT, Hoving E, Loennechen T, Aasen AO, Fodstad O and Maelandsmo GM: S100A4 involvement in metastasis: degradation of matrix metalloproteinases and tissues inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res. 59:4702–4708. 1999.
12.	Mathisen B, Lindstad RI, Hansen J, El-Gewely SA, Maelandsmo GM, Hoving E, Fodstad O, Loennechen T and Winberg JO: S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis. 20:701–711. 2003.
13.	Saleem M, Kweon M-H, Johnson JJ, Adhami MA, Elcheva A, Khan N, Hataluri V and Mukhtar H: S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci USA. 103:14825–14830. 2006.
14.	Gontero P, Banisadr S, Frea B and Brausi M: Metastasis markers in bladder cancer; a review of literature and clinical considerations. Eur Urol. 46:296–311. 2004.
15.	Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M and Kagawa S: Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 expression in bladder cancer. Cancer. 82:1359–1366. 1998.
16.	Furukawa A, Tsuji M, Nishitani T, Kanda K, Inoue Y, Knayama H and Kagawa S: Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency. Urology. 51:849–853. 1998.
17.	Hara I, Miyake H, Hara S, Arakawa S and Kamidono S: Significance of matrix metalloproteinase and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J Urol. 165:1769–1772. 2001.
18.	Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE and Kelly JD: Comprehensive profiling and localization of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer. 94:569–757. 2006.
19.	Ismail NI, Kaur G, Hashim H and Hassan MS: S100A4 overexpression proves to be independent marker for breast cancer progression. Cancer Cell Int. 5:8–12. 2008.
20.	Maruta S, Sakai H, Kanda S, Hayashi T, Kanetake H and Miyata Y: E1AF expression is associated with extra-prostatic growth and matrix metalloproteinase-7 expression in prostate cancer. APMIS. 117:791–796. 2009.
21.	Davies BR, O’Donnell M, Durkan GC, Rudland PS, Barraclough R, Neal DE and Mellon JK: Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol. 196:292–299. 2002.
22.	DeLassus GS, Cho H, Park J and Eliceiri GL: New pathway links from cancer-progression determinants to gene expression of matrix metalloproteinases in breast cancer cells. J Cell Physiol. 217:739–744. 2008.
23.	Agerbaek M, Alsner J, Marcussen N, Lundbeck F and von der Maase H: Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients. Eur Urol. 50:777–785. 2006.